Ameriprise Financial Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ameriprise Financial Inc. cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 326,551 shares of the biopharmaceutical company's stock after selling 40,208 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.30% of Regeneron Pharmaceuticals worth $232,397,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Aptus Capital Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 64.2% in the 4th quarter. Aptus Capital Advisors LLC now owns 1,599 shares of the biopharmaceutical company's stock worth $1,139,000 after buying an additional 625 shares during the last quarter. Aspire Growth Partners LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $421,000. Itau Unibanco Holding S.A. grew its stake in Regeneron Pharmaceuticals by 77.9% in the 4th quarter. Itau Unibanco Holding S.A. now owns 153 shares of the biopharmaceutical company's stock valued at $109,000 after purchasing an additional 67 shares during the period. Westbourne Investments Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $356,000. Finally, Caisse DE Depot ET Placement DU Quebec increased its position in shares of Regeneron Pharmaceuticals by 59.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 310,153 shares of the biopharmaceutical company's stock valued at $220,931,000 after purchasing an additional 115,528 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on REGN. Guggenheim reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Citigroup lowered their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. Finally, Bank of America cut their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $892.60.

Regeneron Pharmaceuticals Trading Down 0.3 %

Shares of REGN opened at $603.58 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1-year low of $525.99 and a 1-year high of $1,211.20. The company has a market capitalization of $65.99 billion, a P/E ratio of 15.77, a P/E/G ratio of 2.34 and a beta of 0.43. The firm's 50 day simple moving average is $624.42 and its 200 day simple moving average is $704.67.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $9.55 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.